Journal
JOURNAL OF FUNCTIONAL FOODS
Volume 67, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jff.2020.103869
Keywords
Kefir; Soy milk; Diabetes; Obesity; Liver-kidney; Histological
Categories
Funding
- Tunisian Ministry of Higher Education and Scientific Research and Technology
- Tunisian Ministry of public heath
Ask authors/readers for more resources
In vitro, this study showed that unfermented soy milk (USM) and kefir fermented soy milk (FSM) inhibited pancreas lipase with (IC50 = 52.17 and 39.37 mu g/mL) and a-amylase activities with (IC50 = 72.60 and 52.71 mu g/mL respectively). The most powerful lipase and a -amylase inhibitory activity was observed around 16 h of fermentation. In HFFD rats, the supplement of FSM increased locomotor performance; and decreased intestinal and pancreas lipase activity by 34 and 35% as compared to untreated HDF-rats. This leads to decrease in TC and LDL-c by 24 and 66%; and increase in HDL-c rates of HFFD-rats by 32%, which helped to decrease in body weight by 20%. Moreover administration of FSM to HFFD-rats inhibited intestinal and pancreas a-amylase activity by 26 and 31% as compared to untreated HFFD-rats, and consequently decrease of blood glucose by 36%. In addition, FSM efficiently was protected from hepatic and kidney tissues toxicities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available